287 related articles for article (PubMed ID: 29463549)
1. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
[No Abstract] [Full Text] [Related]
2. Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.
Kim K; Zhang H; La Rosa S; Jebiwott S; Desai P; Kimm S; Scherz A; O'Donoghue JA; Weber WA; Coleman JA
Clin Cancer Res; 2017 Jul; 23(13):3343-3351. PubMed ID: 28108545
[No Abstract] [Full Text] [Related]
3. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.
O'Shaughnessy MJ; Murray KS; La Rosa SP; Budhu S; Merghoub T; Somma A; Monette S; Kim K; Corradi RB; Scherz A; Coleman JA
Clin Cancer Res; 2018 Feb; 24(3):592-599. PubMed ID: 28954788
[No Abstract] [Full Text] [Related]
4. Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity.
Udayakumar TS; Stoyanova R; Shareef MM; Mu Z; Philip S; Burnstein KL; Pollack A
Mol Cancer Ther; 2016 Jun; 15(6):1353-63. PubMed ID: 26944919
[TBL] [Abstract][Full Text] [Related]
5. Independence of HIF1a and androgen signaling pathways in prostate cancer.
Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.
Olson BM; Gamat M; Seliski J; Sawicki T; Jeffery J; Ellis L; Drake CG; Weichert J; McNeel DG
Cancer Immunol Res; 2017 Dec; 5(12):1074-1085. PubMed ID: 29051161
[TBL] [Abstract][Full Text] [Related]
7. Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
Sjoberg HT; Philippou Y; Magnussen AL; Tullis IDC; Bridges E; Chatrian A; Lefebvre J; Tam KH; Murphy EA; Rittscher J; Preise D; Agemy L; Yechezkel T; Smart SC; Kinchesh P; Gilchrist S; Allen DP; Scheiblin DA; Lockett SJ; Wink DA; Lamb AD; Mills IG; Harris A; Muschel RJ; Vojnovic B; Scherz A; Hamdy FC; Bryant RJ
Br J Cancer; 2021 Aug; 125(4):534-546. PubMed ID: 34155340
[TBL] [Abstract][Full Text] [Related]
8. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
9. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
10. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
11. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Nicholson B; Gulding K; Conaway M; Wedge SR; Theodorescu D
Clin Cancer Res; 2004 Dec; 10(24):8728-34. PubMed ID: 15623658
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
13. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
Mu Z; Hachem P; Hensley H; Stoyanova R; Kwon HW; Hanlon AL; Agrawal S; Pollack A
Prostate; 2008 May; 68(6):599-609. PubMed ID: 18196567
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
15. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
16. Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer.
Sasaki T; Ishii K; Iwamoto Y; Kato M; Miki M; Kanda H; Arima K; Shiraishi T; Sugimura Y
Lab Invest; 2016 Mar; 96(3):338-49. PubMed ID: 26641067
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
18. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
19. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
20. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
